𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance

✍ Scribed by D. N. Moskovitz; C. Osiowy; E. Giles; G. Tomlinson; E. J. Heathcote

Book ID
108885776
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
140 KB
Volume
12
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Response to long-term lamivudine treatme
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
✍ Mariko Kobayashi; Fumitaka Suzuki; Norio Akuta; Yoshiyuki Suzuki; Yasuji Arase; πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 207 KB πŸ‘ 2 views

## Abstract Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24–49] vs. 47 [24–67] or 44 [18–73], __

Entecavir treatment for up to 5 years in
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B
✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 371 KB πŸ‘ 2 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E